<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="correction"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Intensive Care Med</journal-id><journal-id journal-id-type="iso-abbrev">Intensive Care Med</journal-id><journal-title-group><journal-title>Intensive Care Medicine</journal-title></journal-title-group><issn pub-type="ppub">0342-4642</issn><issn pub-type="epub">1432-1238</issn><publisher><publisher-name>Springer-Verlag</publisher-name><publisher-loc>Berlin/Heidelberg</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">4713936</article-id><article-id pub-id-type="publisher-id">2081</article-id><article-id pub-id-type="doi">10.1007/s00134-010-2081-4</article-id><article-categories><subj-group subj-group-type="heading"><subject>Erratum</subject></subj-group></article-categories><title-group><article-title>Erratum to: Design, conduct, analysis and reporting of a multi-national placebo-controlled trial of activated protein C for persistent septic shock</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Finfer</surname><given-names>Simon</given-names></name><address><phone>+61-2-96570348</phone><fax>+61-2-96570301</fax><email>sfinfer@george.org.au</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Ranieri</surname><given-names>V. Marco</given-names></name><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Thompson</surname><given-names>B. Taylor</given-names></name><xref ref-type="aff" rid="Aff3"/></contrib><contrib contrib-type="author"><name><surname>Barie</surname><given-names>Philip S.</given-names></name><xref ref-type="aff" rid="Aff4"/></contrib><contrib contrib-type="author"><name><surname>Dhainaut</surname><given-names>Jean-Fran&#x000e7;ois</given-names></name><xref ref-type="aff" rid="Aff5"/></contrib><contrib contrib-type="author"><name><surname>Douglas</surname><given-names>Ivor S.</given-names></name><xref ref-type="aff" rid="Aff6"/></contrib><contrib contrib-type="author"><name><surname>G&#x000e5;rdlund</surname><given-names>Bengt</given-names></name><xref ref-type="aff" rid="Aff7"/></contrib><contrib contrib-type="author"><name><surname>Marshall</surname><given-names>John C.</given-names></name><xref ref-type="aff" rid="Aff8"/></contrib><contrib contrib-type="author"><name><surname>Rhodes</surname><given-names>Andrew</given-names></name><xref ref-type="aff" rid="Aff9"/></contrib><aff id="Aff1"><label/>Critical Care and Trauma, The George Institute for International Health, University of Sydney, PO Box M201, Missenden Road, Sydney, NSW 2050 Australia </aff><aff id="Aff2"><label/>Ospedale S. Giovanni Battista-Molinette, Universit&#x000e0; di Torino, Torino, Italy </aff><aff id="Aff3"><label/>Pulmonary and Critical Care Unit, Bullfinch Building, Room 148, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114 USA </aff><aff id="Aff4"><label/>Department of Surgery, P713A, Weill Cornell Medical College, 525 East 68 St, New York, NY 10065 USA </aff><aff id="Aff5"><label/>Cochin Port Royal Hospital-Paris Descartes University, Paris, France </aff><aff id="Aff6"><label/>Denver Health and University of Colorado, Denver, USA </aff><aff id="Aff7"><label/>Department of Infectious Diseases, Karolinska University Hospital, 14186 Stockholm, Sweden </aff><aff id="Aff8"><label/>Departments of Surgery and Critical Care Medicine, St Michael&#x02019;s Hospital, 4th Floor Bond Wing, Rm. 4-007, 30 Bond Street, Toronto, ON M5B 1W8 Canada </aff><aff id="Aff9"><label/>Department of Intensive Care Medicine and Anaesthesia, St George&#x02019;s Hospital, London, SW17 0QT UK </aff></contrib-group><pub-date pub-type="epub"><day>25</day><month>11</month><year>2010</year></pub-date><pub-date pub-type="ppub"><year>2011</year></pub-date><volume>37</volume><fpage>372</fpage><lpage>372</lpage><permissions><copyright-statement>&#x000a9; Copyright jointly held by Springer and ESICM 2010</copyright-statement></permissions><related-article related-article-type="corrected-article" id="d30e85" ext-link-type="doi" xlink:href="10.1007/s00134-008-1266-6"/><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Copyright jointly held by Springer and ESICM 2011</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Erratum to: Intensive Care Med (2008) 34:1935&#x02013;1947 DOI 10.1007/s00134-008-1266-6</title><p>Due to an oversight by the authors, incorrect data appeared in Table&#x000a0;<xref rid="Tab1" ref-type="table">2</xref>. The table is reproduced here with the corrected item in bold type.<table-wrap id="Tab1"><label>Table&#x000a0;2</label><caption><p>Serious bleeding rates in clinical trials of drotrecogin alfa (activated)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Study</th><th align="left">Placebo <italic>n</italic> (%)</th><th align="left">DAA <italic>n</italic> (%)</th><th align="left"><italic>P</italic></th></tr></thead><tbody><tr><td align="left">PROWESS</td><td align="left">17 (2.0)</td><td char="." align="char">30 (3.5)</td><td align="left">0.06</td></tr><tr><td align="left">PROWESS (CNS)</td><td align="left">1 (0.1)</td><td char="." align="char">2 (0.2)</td><td align="left">NS</td></tr><tr><td align="left">ADDRESS</td><td align="left">28 (2.2)</td><td char="." align="char">51 (3.9)</td><td align="left">0.01</td></tr><tr><td align="left">ADDRESS (Day 0&#x02013;6)</td><td align="left">15 (1.2)</td><td char="." align="char">31 (2.4)</td><td align="left">0.02</td></tr><tr><td align="left">ADDRESS (CNS)</td><td align="left">5 (0.4)</td><td char="." align="char">6 (0.5)</td><td align="left">0.72</td></tr><tr><td align="left">RESOLVE</td><td align="left">16 (6.8)</td><td char="." align="char">16 (6.7)</td><td align="left">0.97</td></tr><tr><td align="left">RESOLVE (Day 0&#x02013;6)</td><td align="left">8 (3.4)</td><td char="." align="char"><bold>9 (3.8)</bold></td><td align="left">0.83</td></tr><tr><td align="left">RESOLVE (CNS)</td><td align="left">5 (2.1)</td><td char="." align="char">11 (4.6)</td><td align="left">0.13</td></tr><tr><td align="left">ENHANCE</td><td align="left">&#x02013;</td><td char="." align="char">155 (6.5)</td><td align="left">&#x02013;</td></tr></tbody></table><table-wrap-foot><p>Day 0&#x02013;6: any serious bleeding event occurring during the DAA infusion period</p><p><italic>CNS</italic> central nervous system bleeding</p></table-wrap-foot></table-wrap></p></sec></body><back><fn-group><fn><p>The online version of the original article can be found under doi:10.1007/s00134-008-1266-6.</p></fn></fn-group></back></article>